Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 3, 2011, Pages 351-352

  Cornely, O A ^a   Ullmann, A J ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; PLACEBO; POSACONAZOLE; ANTIFUNGAL AGENT;

ANTIBIOTIC PROPHYLAXIS; ASPERGILLOSIS; CANDIDIASIS; DEATH; DRUG EFFICACY; DRUG EXPOSURE; HUMAN; LETTER; MORTALITY; PRIORITY JOURNAL; SCEDOSPORIUM; SYSTEMIC MYCOSIS; TREATMENT FAILURE; TREATMENT RESPONSE; TRICHOSPORONOSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; MORTALITY RATE; PNEUMOCYSTIS PNEUMONIA; PROPHYLAXIS;

EID: 79951811382     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.261     Document Type: Letter

References (5)

1. Jang, S.H., Colangelo, P.M. & Gobburu, J.V. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin. Pharmacol. Ther. 88, 115-119 (2010).
2. Cornely, O.A. et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356, 348-359 (2007).
3. Ullmann, A.J. et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356, 335-347 (2007).
4. Conte, J.E. Jr, Golden, J.A., Krishna, G., McIver, M., Little, E. & Zurlinden, E. Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. Antimicrob. Agents Chemother. 53, 703-707 (2009).
5. Ullmann, A.J. et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob. Agents Chemother. 50, 658-666 (2006).